Abstract
The interaction of non-phosphorylated L-type pyruvate kinase (L-PK) with fructose 1,6-bisphosphate (FBP), which is an allosteric activator of the phosphorylated enzyme, and peptides that mimic the phosphorylatable N-terminal regulatory domain of the enzyme, was studied. It was found that the catalytic activity of the enzyme was not enhanced in the presence of FBP, and this ligand acted as a relatively weak reversible inhibitor of the enzyme activity in the micromolar concentration range. The phosphorylation site analogue peptides RRASVA and RRAAVA had no effect on the activity of the enzyme, while the phosphorylated peptide RRAS(Pi)VA reversibly inhibited the enzyme and this process was characterised by the Ki value 47 μM. As the phosphorylated form of L-PK is a subject of significant allosteric regulation by FBP, it was concluded that phosphorylation should function as a molecular switch of the allosteric properties of this enzyme.
Keywords: Allosteric effector, fructose 1, 6-bisphosphate, L-type pyruvate kinase, N-terminal domain, peptide, phosphoenolpyruvate.
Protein & Peptide Letters
Title:Interaction of Non-Phosphorylated Liver Pyruvate Kinase with Fructose 1,6-Bisphosphate and Peptides that Mimic the Phosphorylatable N-terminus of the Enzyme
Volume: 20 Issue: 11
Author(s): Ilona Faustova and Jaak Järv
Affiliation:
Keywords: Allosteric effector, fructose 1, 6-bisphosphate, L-type pyruvate kinase, N-terminal domain, peptide, phosphoenolpyruvate.
Abstract: The interaction of non-phosphorylated L-type pyruvate kinase (L-PK) with fructose 1,6-bisphosphate (FBP), which is an allosteric activator of the phosphorylated enzyme, and peptides that mimic the phosphorylatable N-terminal regulatory domain of the enzyme, was studied. It was found that the catalytic activity of the enzyme was not enhanced in the presence of FBP, and this ligand acted as a relatively weak reversible inhibitor of the enzyme activity in the micromolar concentration range. The phosphorylation site analogue peptides RRASVA and RRAAVA had no effect on the activity of the enzyme, while the phosphorylated peptide RRAS(Pi)VA reversibly inhibited the enzyme and this process was characterised by the Ki value 47 μM. As the phosphorylated form of L-PK is a subject of significant allosteric regulation by FBP, it was concluded that phosphorylation should function as a molecular switch of the allosteric properties of this enzyme.
Export Options
About this article
Cite this article as:
Faustova Ilona and Järv Jaak, Interaction of Non-Phosphorylated Liver Pyruvate Kinase with Fructose 1,6-Bisphosphate and Peptides that Mimic the Phosphorylatable N-terminus of the Enzyme, Protein & Peptide Letters 2013; 20 (11) . https://dx.doi.org/10.2174/09298665113209990008
DOI https://dx.doi.org/10.2174/09298665113209990008 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuropeptides B, S and W, Obestatin/Ghrelin-Associated Peptide, and Others: Really New Feeding Regulatory Peptides?
Central Nervous System Agents in Medicinal Chemistry Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
Letters in Drug Design & Discovery Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations
Medicinal Chemistry Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research Characterization of the Active Components of the Multimerized sTNFRII-Adiponectin Fusion Protein Showing Both TNFα-Antagonizing and Glucose Uptake-Promoting Activities
Endocrine, Metabolic & Immune Disorders - Drug Targets Calcifediol – More than the Stepchild of CKD-MBD Therapy?
Current Vascular Pharmacology Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Novel Biomaterials for Cartilage Tissue Engineering
Current Rheumatology Reviews Cannabis Abuse and Vulnerability to Psychosis: Targeting Preventive Services
Current Pharmaceutical Design The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?
Current Topics in Medicinal Chemistry “Unlocking” the Blood-Testis Barrier and the Ectoplasmic Specialization by Cytokines During Spermatogenesis: Emerging Targets for Male Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets Reducing the Risk of Type 2 Diabetes - Early Identification of High-Risk Individuals and Treatment with Acarbose
Current Diabetes Reviews From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research